The invention relates to tricyclic heterocyclic derivatives, or pharmaceutically-acceptable salts or in vivo hydrolysable esters thereof, which possess anti-cancer activity. The invention also relates to processes for the manufacture of said tricyclic heterocyclic derivatives, to novel pharmaceutical compositions containing them and to the use of said tricyclic heterocyclic derivatives in the manufacture of a medicament for the production of an anti-cancer effect.
The invention provides an optionally substituted tricyclic heterocyclic derivative of the formula I
wherein A together with the adjacent vinylene group of the 4-oxo-1,4-dihydropyrid-1-yl ring completes a benzene or pyridine ring;
R¹ and R², which may be the same or different, each is (1-4C)alkyl or (1-4C)alkoxy;
and R³ is hydrogen, (1-4C)alkyl or (1-4C)alkoxy;
or a pharmaceutically-acceptable salt or in vivo hydrolysable ester thereof.
该发明涉及
三环杂环衍
生物,或其药用盐或体内可
水解酯,具有抗癌活性。该发明还涉及制备所述
三环杂环衍
生物的方法,含有它们的新型药物组合物以及利用所述
三环杂环衍
生物制造抗癌药物以产生抗癌效果的用途。该发明提供了公式I的可选择取代的
三环杂环衍
生物,其中A与4-氧代-1,4-
二氢吡啶-1-基环的相邻
乙烯基团共同形成苯环或
吡啶环;R¹和R²,可以相同也可以不同,分别是(1-4C)烷基或(1-4C)烷氧基;R³是氢,(1-4C)烷基或(1-4C)烷氧基;或其药用盐或体内可
水解酯。